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ELL-associated protein 30 (EAP30) was initially characterized as a component of the Holo–ELL com-
plex, which contains the elongation factor ELL. Both ELL and Holo–ELL stimulate RNA pol II elonga-
tion in vitro. However, ELL and not Holo–ELL inhibits RNA pol II initiation. It is not clear how these
two discrete functions of ELL are regulated. Here we report that mini-chromosome maintenance 2
(MCM2) binds to EAP30 and show that MCM2 competes with ELL for binding to EAP30 thus poten-
tially modulating the stability of Holo–ELL.
Structured summary:
MINT-7277033: EAP30 (uniprotkb:Q96H20) physically interacts (MI:0915) with RPB1 (uniprotkb:P24928)
by anti tag coimmunoprecipitation (MI:0007)
MINT-7277085: EAP30 (uniprotkb:Q96H20) binds (MI:0407) to ELL (uniprotkb:P55199) by pull down
(MI:0096)
MINT-7277072: EAP30 (uniprotkb:Q96H20) physically interacts (MI:0915) with ELL (uniprotkb:P55199)
by anti tag coimmunoprecipitation (MI:0007)
MINT-7277100: EAP30 (uniprotkb:Q96H20) physically interacts (MI:0915) with ELL (uniprotkb:P55199)
by competition binding (MI:0405)
MINT-7277153: MCM2 (uniprotkb:P49736) binds (MI:0407) to ELL (uniprotkb:P55199) by pull down
(MI:0096)
MINT-7276989: EAP30 (uniprotkb:Q96H20) physically interacts (MI:0915) with MCM2 (uni-
protkb:P49736) by pull down (MI:0096)
MINT-7277005: EAP30 (uniprotkb:Q96H20) physically interacts (MI:0915) with RPB1 (uniprotkb:P24928)
by pull down (MI:0096)
MINT-7276960, MINT-7277168: MCM2 (uniprotkb:P49736) physically interacts (MI:0915) with EAP30
(uniprotkb:Q96H20) by two hybrid (MI:0018)
MINT-7276971, MINT-7277121, MINT-7277137: MCM2 (uniprotkb:P49736) binds (MI:0407) to EAP30
(uniprotkb:Q96H20) by pull down (MI:0096)
MINT-7277018, MINT-7277061: EAP30 (uniprotkb:Q96H20) physically interacts (MI:0915) with MCM2
(uniprotkb:P49736) by anti tag coimmunoprecipitation (MI:0007)
Crown Copyright  2009 Published by Elsevier B.V. on behalf of Federation of European Biochemical
society. All rights reserved.1. Introduction scription [3]. Structure–function analyses have indicated that inhi-Eleven–nineteen lysine-rich leukemia (ELL) has been initially
identiﬁed as a gene that undergoes translocations withMLL (mixed
lineage leukemia) in acute myeloid leukemia [1]. Independently,
ELL has been puriﬁed as a RNA pol II elongation factor [2], which
also acts as a potent suppressor of the initiation of RNA pol II tran-d by Elsevier B.V. on behalf of Fede
kemia; EAP30,ELL-associated
ChB, chromatography buffer;
te gels
ov).bition of initiation but not stimulation of elongation in vitro was
suppressed by the removal of the ﬁrst 50 N-terminal amino acids
of ELL [3]. Interestingly, the MLL–ELL translocations, which are
found in patients with acute myeloid leukemia, produce similar
deletions of the N-terminus of ELL [1,4].
Studies in Drosophila have shown that dELL associates with ac-
tively elongating RNA polymerase II and plays an essential role in
development [5,6]; and that it regulates poised RNA pol II at the
Hsp70 and other promoters [7]. Therefore, ELL has emerged as a
general RNA pol II initiation/elongation factor. However, N-termi-
nal dELL deletion mutants, which lack the domain essential for
its targeting to sites of active transcription, still support viabilityration of European Biochemical society. All rights reserved.
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function as a general pol II factor [8]. In agreement, over-expres-
sion of ELL causes transformation of RAT1 cells [4] or growth inhi-
bition/apoptosis in HEK293 cells [9] again suggesting a role in
addition to its function as a pol II transcription factor. A third line
of study has revealed that ELL acts as a positive co-regulator of the
mineralocorticoid receptor but negative regulator of the glucocor-
ticoid receptor [10].
In rat liver extracts ELL has been found in a stable complex with
three proteins, EAP45, EAP30 and EAP22, to form the so-called
Holo–ELL [11]. Unlike ELL, Holo–ELL does not suppress transcrip-
tional initiation in vitro suggesting that the associated proteins
regulate this activity [11]. Of these, EAP30 alone can interact with
ELL and reverse the inhibitory effect of ELL on initiation [12]. Sep-
arately, EAP30 has been characterized as the VPS22 component of
the endosomal trafﬁcking complex ESCRT-II and has been impli-
cated in telomere length regulation [13] or in the association with
bicoid RNA [14]. It is not clear if this form of EAP30 regulates ELL or
if it has a completely independent role. In summary, the signiﬁ-
cance of the ELL-EAP30 interaction remains elusive. Here we report
that mini-chromosomemaintenance 2 (MCM2) binds to EAP30 and
interferes with the ELL-EAP30 association.
2. Materials and methods
2.1. Two-hybrid screen
Two-hybrid screen was performed with pGBKT7-MCM2(1–230)
as bait and Hela Matchmaker cDNA library (Clontech). Two-hybrid
interaction and a-galactosidase assays were performed with
pGBKT7-MCM2(1–230) and a set of pGAD-GH-EAP30 deletion mu-
tants (shown in Fig. 2) according to the instructions of the manu-
facturer (Clontech).
2.2. Vectors
Vectors for the expression of His6-MCM2 (pRSET-BM28) [15],
GST-MCM2(1–169) and GST-MCM2(1–230) [16] were described
previously. EAP30 expression vectors were produced by PCR and
sub-cloning of full-length EAP30 in pGEX2T (Pharmacia), pFLAG-
CMV-2 (Sigma), pcDNA3.1 (Invitrogen), pET28b (Novagen) and
pGAD-GH (Clontech), respectively. pGBKT7-MCM2(1-169) and
pGBKT7-MCM2(1–230) were produced by PCR and sub-cloning
into pGBKT7. pET28-hisELL was produced by sub-cloning the NotI
fragment from pFLAG-ELL [17].
2.3. Cell transformation and immunoprecipitation
HEK293 cells were grown in 10 cm plates to 50% conﬂuency in
DMEM/10% FBS. For the experiment in Fig. 1D, each plate was
transfected with 10 lg of pFLAG-EAP30 plus 20 lg of carrier plas-
mid (pBluescript) by calcium phosphate-precipitation. For the co-
expression of MYC-EAP30 and FLAG-ELL in Fig. 3a each plasmid
was used at 10 lg without carrier. Cells were harvested 36–48 h
post-transfection and extracts were prepared as in [16]. Lysates
were immunoprecipitated with 2 lg of anti-FLAG M2 (Sigma)
and 20 ll of Protein-G-Agarose (Sigma) or 20 ll of anti-MYC-Aga-
rose (Sigma). Beads were washed four times with 1 ml buffer and
eluted in SDS-loading buffer. Western blot analysis was performed
with anti-RPB1(8WG16), anti-(BM28) [15] or anti-Enolase1 [18].
Anti-MYC and anti-FLAG-M2 antibodies were from Sigma.
2.4. Expression of His6-tagged proteins
His6-ELL was expressed from pET28a-hisELL in BL21(LysS)DE3
for 2 h at 30 C. Cells were lysed in Chromatography buffer (ChB:50 mM NaCl, 20 mM Na–HEPES 7.9, 0.2 mM EDTA, 0.2 mM EGTA,
5 mM 2-glycerophosphate, 0.05% NP-40, 12% glycerol, 1 lg/mL
pepstatin, 1 lg/mL leupeptin, 2 lg/mL aprotonin, 50 lg/mL PMSF)
and extracts were spun for 15 min at 15 000 rpm in a Sorvall
SA300. His6-ELL was found in the insoluble pellet. About 100 ll
of the pellet was suspended in 1 ml of 7 M guanidine hydrochlo-
ride and renatured by stepwise dialysis to 0.09 M guanidine
hydrochloride. The renatured proteins were then loaded on Ni-
NTA Agarose (Qiagen). His6-MCM2 was expressed from pRSET-
BM28 in BL21(LysS)DE3 for 2 h at 30 C as directed by the man-
ufacturer (Invitrogen). His6-EAP30 was expressed from pET28b-
EAP30 in BL21(LysS)DE3 for 2 h at 30 C. In both cases, cell lysates
in ChB were spun for 15 min at 15 000 rpm, the supernatants
were supplemented with 0.1% NP-40 and loaded on Ni-NTA Aga-
rose (Qiagen). Ni-NTA beads were then washed with ChB/2 mM
Imidazole and eluted stepwise with 50 mM and 300 mM Imidaz-
ole in ChB. The peak fractions were pooled and snap-frozen. For
the experiments in Fig. 3, the partially puriﬁed proteins were
thawed, buffer-exchanged to ChB through Biospin P-6 columns
(Bio-Rad) and immediately applied to beads containing GST-fu-
sion proteins.
2.5. GST-afﬁnity chromatography and GST pull-down assays
GST, GST-MCM2(169–230), GST-MCM2(1–230) and GST-EAP30
were expressed from pGEX and cells were lysed in ChB. Lysates
were incubated with Glutathione-Sepharose-4B (Pharmacia) to
yield about 1–2 mg of full-length protein per ml resin as estimated
by boiling an aliquot of the resin and running the sample on poly-
acrylamide–sodium dodecyl sulfate gels (PAGE–SDS) gels. Control
GST beads contained about 5 mg protein per ml of resin. For the
afﬁnity chromatography experiments in Fig. 1b and c 100 ll beads
were transferred to 1 ml columns (Bio-Rad) and loaded with 1 ml
HeLa whole cell extract prepared as in [15]. Extracts were passed
three times through the beads, the beads were washed four times
with 1 ml ChB and eluted with ChB/1 M NaCl. For the pull-down
assays in Fig. 3b and c 15 ll beads were transferred to 1.5 ml tubes
and were incubated with different combinations of His6-tagged
proteins for 45 min at 4 C. Beads were washed four times with
1 ml ChB and then boiled in SDS-loading buffer before analysis
by PAGE–SDS/Coomassie.
3. Results and discussion
3.1. EAP30 interacts with the N-terminus of MCM2
We have performed an yeast two-hybrid screen using the
MCM2 N-terminal amino acids 1–230 ((MCM2(1–230)) as bait.
Among other meaningful preys we pulled out EAP30 (Fig. 1a) and
conﬁrmed the EAP30-MCM2 interaction by afﬁnity chromatogra-
phy with bacterially over-expressed proteins (Fig. 1b). Removal
of the N-terminal 169 amino acids ((MCM2(169–230)) dramati-
cally reduced this interaction in both assays (Fig. 1a and b). On
the other hand, the previously reported association with RNA pol
II ‘‘holoenzyme” [16] was critically dependent on the 169–230
and not on the 1–169 amino acids of MCM2. The MCM2(1–169)
protein proved to be unstable in both systems thus precluding di-
rect test on its interaction with EAP30. Together, these analyses
have shown that EAP30 associates with MCM2 via a domain dis-
tinct from the one mediating the MCM2-RNApol II ‘‘holoenzyme”
interaction.
We extended the initial observations by analysis of the associa-
tion of EAP30 with native proteins in mammalian cell extracts. In
the ﬁrst set of experiments, GST and GST-EAP30 were expressed
in E. coli and immobilized on Glutathione-Sepharose. Subse-
quently, HeLa whole cell extract prepared as in [15] was passed
Fig. 1. EAP30 interacts with the N-terminus of MCM2. (a) AH109 cells were transformed with pGAD-EAP30 and pGBKT7, pGBKT7-MCM2(169-212) or pGBKT7-MCM2(1–230)
as shown on top and plated on SD-trp-leu or SD-trp-leu-his-ade agar. (b) GST, GST-MCM2(169-212) or GST-MCM2(1–230) beads (100 ll) were loaded with 50 lg of His6-
EAP30. Columns were washed extensively and eluted with 1 M NaCl. 10% of the Load, ﬁnal Wash and Eluate fractions were resolved on a 12% SDS–PAGE gel and stained with
Coomassie. The ﬁgure represents one of two independent experiments. (c) GST or GST-EAP30 (100 ll) were loaded with 10 mg of HeLa cell extract, washed extensively and
eluted with 1 M NaCl. 10% of the Load and Flowthrough (FT), and 30% of the ﬁnal Wash and Eluate fractions were analyzed by Western blot. This ﬁgure represents one of two
independent experiments. (d) Control HEK293 cells (lanes 1 and 2) or cells expressing FLAG-EAP30 (lanes 3 and 4) were immunoprecipitated with anti-FLAG antibody. 10% of
each lysate (L) and 40% of immunoprecipitated fractions (IP) were resolved on a 12% SDS–PAGE gel and analyzed by Western blot. The ﬁgure represents one of three
independent experiments.
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with 1 M NaCl. All fractions were analyzed by Western blot with
anti-RPB1, anti-MCM2 and anti-Enolase 1 antibodies. As shown
in Fig. 1c, a signiﬁcant proportion of RPB1 and MCM2, but not Eno-
lase 1 were retained by the GST-EAP30 and not by the GST beads.
In a second set of experiments a FLAG-tagged EAP30 was over-ex-
pressed in HEK293 cells and extracts were analyzed by immuno-
precipitation with anti-FLAG antibodies. The co-precipitating
proteins were analyzed by Western blot. We detected 8% of RPB1
and 2.5% of MCM2, but no Enolase 1, in the anti-FLAG immunopre-
cipitates (Fig. 1d). The lower percent of recovery of MCM2 is not
surprising as this protein is signiﬁcantly more abundant than
RPB1 [19]. These data corroborated the notion of MCM2-EAP30
interaction. An interesting aspect of the experiments in Fig. 1c
and d was the consistent co-puriﬁcation of RPB1 (and arguablyRNA pol II) with EAP30. Earlier studies have reported an interaction
between ELL and RNA pol II and between ELL and EAP30, respec-
tively [3,12], but not directly between EAP30 and RNA pol II. It re-
mained unclear if the association of ELL to EAP30 and to RNA pol II
were mutually exclusive. Our results suggest that they are not and
that EAP30 co-immunoprecipitates RNA pol II through interactions
with Holo–ELL. More importantly, the results in Fig. 1 demonstrate
the association between MCM2 and EAP30 by four independent
assays.
3.2. EAP30 interacts with MCM2 via its N-terminus
Next, we performed structure–function analyses of EAP30 using
the yeast two-hybrid system. Different N- and C-terminal frag-
ments of EAP30 were cloned in pGAD-GH to produce expression
Fig. 2. The N-terminus of EAP30 interacts with MCM2(1–230). EAP30 deletion mutants fused to the GAL4 Activation Domain in pGAD-GH were co-transformed with pGBKT7-
MCM2(1–230) into AH109 cells and assayed for a-galactosidase activity. For each construct three colonies were assayed and the mean activities are plotted as a percentage
relative to full-length GAL4AD-EAP30(1–258) in the graph on the left. Bracketed numbers on the left correspond to the EAP30 amino acid residues encoded in the construct.
Transformants were also grown for on SC-trp-leu-his-ade plates and scored for growth (+), weak growth (+/) and no growth () as shown on the right. The ﬁgure represents
one of two independent experiments. Error bars represent S.D. of triplicate a-galactosidase assays.
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transformed in AH109 cells (Clontech) harbouring pGAL4-DBD-
MCM2(1–230). Western blot indicated that all EAP30-fusion pro-
teins were expressed at similar levels (not shown). Subsequently,
we tested the ability of these fusion proteins to support growth
on quadruple drop-out medium or by measuring a-galactosidase
activity of cells grown in double drop-out medium. The results of
both assays showed that removal of the N-terminal 48 amino acids
of EAP30 reduced binding to MCM2 by 75% while removal of the N
terminal 1–98 amino acids precluded the association of the two
proteins. C-terminal deletion reduced binding to MCM2 as mea-
sured by the a-galactosidase assay but still supported growth
(Fig. 2). Together, the data show that the N-terminus of EAP30
plays a critical role in its interaction with MCM2.
We attempted similar analyses with ELL cloned in pGBKT7. Sur-
prisingly, neither the cell growth nor the a-galactosidase assays re-
vealed any interaction between EAP30 and ELL (not shown).
Because ELL expression was detected by Western blot, we attribute
this lack of interaction to misfolding of ELL or to blocking of its N-
terminus in the fusion protein. We concluded that the two-hybrid
system is not adequate for analysis of the EAP30-ELL interaction.
3.3. MCM2 and ELL compete for binding to EAP30
Despite the negative result in the two-hybrid assay, there is a
well-documented interaction between EAP30 with ELL [12]. We
therefore attempted analyses by transient transfection in HEK293
cells using FLAG-ELL and MYC-EAP30. Indeed, we noticed that
about 20% of FLAG-ELL in the load was immunoprecipitated by
the anti-MYC antibodies (Fig. 3a, lane 5). Interestingly, no endoge-
nous MCM2 was seen in these samples (Fig. 3a, lane 5). In contrast,
when MYC-EAP30 was expressed alone, about 3% of endogenous
MCM2 was immunoprecipitated (Fig. 3a, lane 6). It is noteworthy
that HEK293 do not express signiﬁcant amounts of endogenous
ELL [9]. So, it is conceivable that over-expression of ELL competes
with MCM2 for EAP30. Still, the complexity of cell extracts com-
bined with the over-expression of EAP30 and ELL offer limited con-
ﬁdence in this conclusion.
We revisited the idea of competition between ELL and MCM2
for EAP30 by performing pull-down assays in a deﬁned systemwith bacterially expressed His6-ELL, His6-MCM2 and GST-EAP30.
His6-ELL was expressed and renatured as in [12]. This procedure
generates ELL, which interacts with EAP30 and RNA pol II [12].
His6-MCM2 was expressed as in [15]. Both His6-ELL and His6-
MCM2 were partially puriﬁed on Ni-NTA-Agarose and snap-frozen.
Purity and abundance of the puriﬁed proteins were estimated by
PAGE–SDS gels (Fig. 3b, lanes 3 and 4). To avoid aggregation during
dialysis, His6-ELL and His6-MCM2 were buffer-exchanged through
spin columns immediately before adding to GST-EAP30 beads.
His6-ELL or His6-MCM2 did not bind to GST (Fig. 3b, lanes 16 and
17). The GST-EAP30 beads were incubated for 45 min with differ-
ent concentrations of His6-ELL and His6-MCM2 (Fig. 3b, lanes 5–
14), washed and analyzed by PAGE–SDS/Coomassie stain. In
Fig. 3b we show that His6-MCM2 alone (lane 5) or His6-ELL alone
(lane 10) were retained by GST-EAP30 at levels permitting visual-
ization by Coomassie stain. When His6-MCM2 was premixed with
His6-ELL, even low amounts of His6-ELL were efﬁcient in the dis-
placing of EAP30-bound His6-MCM2 (Fig. 3b, lanes 6–9). In con-
trast, when EAP30-bound His6-ELL was challenged by His6-
MCM2, little His6-ELL was displaced (Fig. 3b, lanes 11–14). These
data indicate that His6-ELL and His6-MCM2 independently interact
with EAP30, however the EAP30-ELL interaction is favoured.
We performed a similar experiment with GST-MCM2(1–230) as
an afﬁnity ligand (Fig. 3c). These beads were incubated with His6-
EAP30 (lane 5) or His6-ELL (lane 10) alone and with increasing
amounts of His6-ELL (lanes 6–9) or His6-EAP30 (lanes 11–14),
respectively. We observed that His6-ELL and His6-EAP30 bind indi-
vidually to GST-MCM2(1–230) (Fig. 3d, lanes 5 and 10), but mixing
them precludes the binding of both. We conclude that MCM2, ELL
and EAP30 can compete for interacting with each other with
EAP30-ELL being the preferred interaction.
MCM2 is measured at more than 106 copies in proliferating cells
[19], however its abundance is dramatically reduced in quiescent
cells including hepatocytes [20]. The abundance of ELL in quiescent
and proliferating cells has not been established [21,22], however
the highest levels of expression of ELL mRNA are observed in the
liver [21]. Interestingly, Holo–ELL had been puriﬁed from rat livers
where this complex is likely to be unchallenged by MCM2. Con-
versely, Holo–ELL, which is maintained mostly through the ELL–
EAP30 interaction [12], may be unstable in proliferating cells due
Fig. 3. ELL and MCM2 compete for binding to EAP30. (a) HEK293 cells were transfected with pcDNA-MYC-EAP30 alone or pcDNA-MYC-EAP30 and pFLAG-ELL as indicated.
Extracts were immunoprecipitated with anti-MYC antibody. 10% of each load (L) and 30% of each immunoprecipitate (IP) were resolved on SDS–PAGE gels and analyzed by
Western blot. The ﬁgure represents one of two independent experiments. (b) GST-EAP30 beads (15 ll) were incubated with 20 lg of His6-MCM2 (lanes 5–9) or 20 lg of His6-
ELL (lanes 10–14). The samples in lanes 6–9 received 4, 10, 20 and 40 lg of His6-ELL. The samples in lanes 11–14 received 4, 10, 20 and 40 lg of His6-MCM2. All samples were
brought to 200 ll with buffer. The beads were rocked for 45 min at 4 C, washed and analyzed on 10% PAGE–SDS gels followed by Coomassie staining. GST-EAP30, His6-ELL
and His6-MCM2 alone were run in lanes 2–4. Mobility standards (Fermentas) were run in lanes 1 and 18. The positions of GST-EAP30, His6-ELL and His6-MCM2 are shown.
The identity of His6-MCM2 (apparent mobility of about 130 kDa) has been conﬁrmed by Western blot. In lanes 15–17 GST beads (15 ll) were incubated with 20 lg His6-ELL
or His6-MCM2, washed and analyzed on 15% PAGE–SDS gels. (c) GST-MCM2(1–230) beads (15 ll) were incubated with 20 lg of His6-EAP30 (lanes 5–9) or 20 lg of His6-ELL
(lanes 10–14). The samples in lanes 6–9 received 4, 10, 20 and 40 lg of His6-ELL. The samples in lanes 11–14 received 4, 10, 20 and 40 lg of His6-EAP30. All samples were
brought to 200 ll with buffer. The beads were rocked for 45 min at 4 C, washed and analyzed on 12.5% PAGE–SDS gels followed by Coomassie staining. GST-MCM2(1–230),
His6-ELL and His6-EAP30 alone were run in lanes 2–4. The positions of GST-MCM2(1–230), His6-ELL and His6-EAP30 are shown. In lanes 15–17 GST beads (15 ll) were
incubated with 20 lg His6-ELL or His6-EAP30, washed and analyzed on 15% PAGE–SDS gels.
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will be released to execute its pol II transcription inhibitory activity
[12]. Our data suggest that the functional signiﬁcance of Holo–ELL
should be addressed in non-proliferating tissues rather than in
dividing cells. The same notion can also explain the apparent dis-crepancy in the effects of exogenous expression of ELL in RAT1
[4] or HEK293 [9] cells. More importantly, our study is consistent
with the idea that the activity of ELL is modulated in proliferating
and quiescent cells by the differential abundance of MCM2 thus
linking it to growth and senescence.
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